ARGININE TREATMENT FOR ALCOHOLIC HEPATITIS

精氨酸治疗酒精性肝炎

• 批准号: 7952248
• 负责人: JOEL DAVID KOPPLE
• 金额: $ 2.05万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7952248
• 关键词: Abdomen; Albumins; Alcoholic Hepatitis; Arginine; Ascites; Blood Tests; Clinical; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Diet; Eating; Effectiveness; Energy Intake; Funding; Glucose; Grant; Ice Cream; Infusion procedures; Injury; Institution; Left; Leucine; Liquid substance; Liver; Measurement; Measures; Patients; Placebos; Powder dose form; Radioactive; Radioisotopes; Research; Research Personnel; Resources; Source; Testing; Time; United States National Institutes of Health; arginine treatment

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to test the effectiveness of dietary arginine to reduce liver injury as measured by blood tests. There will be two groups. The first group will have dietary arginine added to their diet in the form of powder mixed into ice cream or sherbet at 4 times the normal amount in the diet. Since the normal amount of arginine in the diet is approximately 1% of the energy intake, you will receive 4% of the energy in the diet as arginine. The second group will receive the placebo treatment consisting of glucose powder added into the ice cream or sherbet in the diet. Patients are entered into the study if they have mild and moderate alcoholic hepatitis. This is determined by having a DF score <33. The DF score is a standard marker of liver injury. Patients will spend 28-30 days in the General Clinical Research Center (GCRC) to measure the effects of additional arginine in the diet. After clinical stability is established, study patients will have several tests and and will also have measurement of how much albumin their liver makes using non-radioactive infusion of leucine. In addition, albumin loss will be measured twice by using a radioisotope of albumin. They will not have this test if the patient has ascites (fluid in the abdomen). Patients will be encouraged to eat 80% or more of their diet. If they are not able to ingest at least 80% of their diet, they will asked to leave the study early.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项研究的目的是测试饮食精氨酸减少肝脏损伤的有效性，通过血液测试来测量。将有两组。第一组将以粉末的形式将精氨酸添加到他们的饮食中，并将其混合到冰淇淋或果子露中，其量是饮食中正常量的4倍。由于饮食中精氨酸的正常量约为能量摄入量的1%，因此您将获得饮食中4%的能量作为精氨酸。第二组将接受安慰剂治疗，包括将葡萄糖粉加入饮食中的冰淇淋或果子露中。如果患者患有轻度和中度酒精性肝炎，则可以进入研究。这通过具有DF分数<33来确定。DF评分是肝损伤的标准标志物。 患者将在综合临床研究中心（GCRC）度过28-30天，以测量饮食中额外精氨酸的影响。 在临床稳定性建立后，研究患者将进行几项测试，并且还将使用非放射性亮氨酸输注测量其肝脏产生多少白蛋白。此外，将使用白蛋白的放射性同位素测量两次白蛋白损失。如果患者有腹水（腹腔积液），则不会进行此测试。 患者将被鼓励吃80%或更多的饮食。如果他们不能摄取至少80%的饮食，他们将被要求提前退出研究。